1921
Volume 78, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

causes debilitating but usually non-lethal malaria in most of Asia and South America. Prevention of relapse after otherwise effective therapy for the acute attack requires a standard daily dose of primaquine administered over 14 days. This regimen has < 90% efficacy in Thailand, and is widely regarded as ineffective because of poor compliance over the relatively long duration of dosing. We evaluated the efficacy, safety, and tolerability of alternative primaquine dosing regimens combined with artesunate among 399 Thai patients with acute, symptomatic malaria. Patients were randomly assigned to one of six treatment groups: all patients received artesunate, 100 mg once a day for 5 days. Groups 1–5 then received primaquine, 30 mg a day for 5, 7, 9, 11, and 14 days, respectively. Group 6 received primaquine, 30 mg twice a day for 7 days. The 28-day cure rates were 85%, 89%, 94%, 100%, and 96%, respectively. Treatment of malaria with artesunate for 5 days followed by high-dose primaquine, 30 mg twice a day for 7 days, was highly effective, well-tolerated, and equivalent or superior to the standard regimen of primaquine therapy.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.2008.78.736
2008-05-01
2017-11-22
Loading full text...

Full text loading...

/deliver/fulltext/14761645/78/5/0780736.html?itemId=/content/journals/10.4269/ajtmh.2008.78.736&mimeType=html&fmt=ahah

References

  1. Krotoski WA, Colllins WE, Bray RS, Garnham PC, Gogswell FB, Gwadz R, Killick-Kendrick R, Wolf RH, Sinden R, Koontz LC, Stanfill PS, 1982. Demonstarion of hypnozoites in sporozoite transmitted Plasmodium vivax infection. Am J Trop Med Hyg 31 : 1291–1293.
  2. Mendis K, Sina BJ, Marchesini P, Carter R, 2001. The neglected burden of Plasmodium vivax malaria. Am J Trop Med Hyg 64 (Suppl) : 97–106.
  3. Bunnag D, Karbwang J, Thanavibul A, Chittamas S, Rattanapong Y, Chalermrut K, Bangchang KN, Harinasuta T, 1994. High dose of primaquine in primaqune resistant vivax malaria. Trans R Soc Trop Med Hyg 88 : 218–219.
  4. Looareesuwan S, Buchachart K, Wilairatana P, Chalermrut K, Rattanapong Y, Amradee S, Siripipat S, Chullavichit S, Thimasarn K, Ittiverakul M, Triampon A, Walsh DS, 1997. Primaquine-tolerant vivax malaria in Thailand. Ann Trop Med Parasitol 91 : 939–943.
  5. Doherty JF, Day JH, Warhurst DC, Chiodini PL, 1997. Treatment of Plasmodium vivax malaria—time for a change? Trans R Soc Trop Med Hyg 88 : 218–219.
  6. Looareesuwan S, Wilairatana P, Krudsood S, Treeprasertsuk S, Singhasivanon P, Bussaratid V, Chokejindachai W, Virayavejakul P, Chalermrut K, Walsh DS, White NJ, 1999. Chloroquine sensitivity of Plasmodium vivax in Thailand. Ann Trop Med Parasitol 93 : 225–230.
  7. Wilairatana P, Silachamroon U, Krudsood S, Singhasivanon P, Treeprasertsuk S, Bussaratid V, Phumratanaprapin W, Srivilairit S, Looareesuwan S, 1999. Efficacy of primaquine regimens for primaquine-resistant Plasmodium vivax malaria in Thailand. Am J Trop Med Hyg 61 : 973–977.
  8. Silachamroon U, Krudsood S, Treeprasertsuk S, Wilairatana P, Chalermrut K, Myint HY, Maneekan P, White NJ, Gourdeuk VR, Brittenham GM, Looareesuwan S, 2003. Clinical trial of oral artesunate with or without high-dose primaquine for the treatment of vivax malaria in Thailand. Am J Trop Med Hyg 69 : 14–18.
  9. Looareesuwan S, Wilairatana P, Glanarongran R, Indravijit KA, Supeeranontha L, Chinnapha S, Scott TR, Chulay JD, 1999. Atovaquone and proguanil hydrochloride followed by primaquine for treatment of Plasmodium vivax malaria in Thailand. Trans R Soc Trop Med Hyg 93 : 637–640.
  10. Bunnag D, Karbwang J, Thanavibul A, Chittamas S, Ratanapongse Y, Chalermrut K, Bangchang KN, Harinasuta T, 1994. High dose of primaquine in primaquine resistant vivax malaria. Trans R Soc Trop Med Hyg 88 : 218–219.
  11. Looareesuwan S, Wilairatana P, Krudsood S, Singhasivanon P, Treeprasertsuk S, Bussaratid V, Chokjindachai W, Viriyavejakul P, Chalermrut K, Walsh DS, White NJ, 1999. Chloroquine sensitivity of Plasmodium vivax in Thailand. Ann Trop Med Parasitol 93 : 225–230.
  12. Baird JK, Hoffman SL, 2004. Primaquine therapy for malaria. Clin Infect Dis 39 : 1336–1345.
  13. Clayman CB, Arnold J, Hochwald RS, Yount EH, Edgcomb JH, Alving AS, 1952. Toxicity of primaquine in Caucasians. JAMA 149 : 1563–1568.
  14. Hansen JE, Cleve EA, Pruitt FW, 1954. Relapse of vivax malaria treated with primaquine and report of one case of cyanosis (methemoglobinemia) due to primaquine. Am J Med Sci 227 : 9–12.
  15. Alving AS, Johnson CF, Tarlov AR, Brewer GJ, Kellermeyer RW, Carson PE, 1960. Mitigation of the hemolytic effect of primaquine and enhancement of its action against exoerythrocytic forms of the Chesson strain of Plasmodium vivax by intermittent regimens of drug administration. Bull World Health Organ 22 : 621–631.
  16. Charoenlarp P, Areekul S, Pholphoti T, Harinasuta T, 1973. The course of primaquine induced hemolysis in G6PD deficient Thais. J Med Assoc Thai 56 : 392–397.
  17. Buchachart K, Krudsood S, Singhasivanon P, Treeprasertsuk S, Phophak N, Srivilairit S, Chalermrut K, Ratttanapong Y, Supeeranuntha L, Wilairatana P, Brittenham GM, Looareesuwan S, 2001. Effect of primaquine standard dose (15 mg/day for 14 days) in the treatment of vivax malaria patients in Thailand. Southeast Asian J Trop Med Public Health 32 : 720–726.
  18. Looareesuwan S, Olliaro P, White NJ, Chongsuphajaisiddhi T, Sabcharoen A, Thimasarn K, Nosten F, Singhasivanon P, Supavej S, Khusmith S, Wyling S, Kanyok T, Walsh D, Leggat PA, Doberstyn EB, 1998. Consensus recommendation on the treatment of malaria in Southeast Asia. Southeast Asian J Trop Med Public Health 29 : 355–360.
  19. Baird JK, Rieckmann KH, 2003. Can primaquine therapy for vivax malaria be improved? Trends Parasitol 9 : 115–120.
  20. Looareesuwan S, White NJ, Chittamas S, Bunnag D, Harinasuta T, 1987. High rate of Plasmodium vivax relapse following treatment of falciparum malaria in Thailand. Lancet 2 : 1052–1055.
  21. Krudsood S, Wilairatana P, Mason DP, Treeprasertsuk S, Singhasivanon P, Looareesuwan S, 1999. Hidden Plasmodium falciparum infections. Southeast Asian J Trop Med Public Health 30 : 623–624.
  22. Mason DP, Krudsood S, Wilairatana P, Viriyavejakul P, Silachamroon U, Chokejindachai W, Singhasivanon P, Supavej S, McKenzie FE, Looareesuwan S, 2001. Can treatment of P. vivax lead to unexpected appearance of falciparum malaria? Southeast Asian J Trop Med Public Health 32 : 57–63.
  23. Snounou G, White NJ, 2004. The co-existence of Plasmodium: sidelights from falciparum and vivax malaria in Thailand. Trends Parasitol 20 : 333–339.
  24. Gustafsson LL, Walker O, Alvan G, Beermann B, Estevez F, Gliesner L, Lindstrom B, Sjoqvist F, 1983. Disposition of chloroquine in man after single intravenous and oral doses. Br J Clin Pharmacol 15 : 471–479.
  25. Baird JK, Wiady I, Fryauff DJ, Sutanihardja MA, Leksana B, Widjaya H, Kysdarmanto, Subianto B, 1997. In vivo resistance to chloroquine by Plasmodium vivax and Plasmodium falciparum at Nabire, Irian Jaya, Indonesia. Am J Trop Med Hyg 56 : 627–631.
  26. Walker O, Dawodu AH, Adeyokunnu AA, Salako LA, Alvan G, 1983. Plasma chloroquine and desethylchloroquine concentrations in children during and after chloroquine treatment of malaria. Br J Clin Pharmacol 16 : 701–705.
  27. White NJ, Milller KD, Churchill FC, Berry C, Brown J, Williams SB, Greenwood BM, 1988. Chloroquine treatment of severe malaria in children. Pharmacokinetics, toxicity, and new dosage recommendations. N Engl J Med 319 : 1493–1500.
  28. Beutler E, Glumbe KG, Kaplan JC, Lohr GW, Romot B, Valentine WN, 1979. International committee for standardization in hematology: recommended screening test for glucose-6-phosphate dehydrogenase (G-6-PD) deficiency. Br J Haematol 43 : 465–467.
  29. Frank JE, 2005. Diagnosis and management of G6PD deficiency. Am Fam Physician 72 : 1277–1282.
  30. Baird JK, Basri H, Subianto B, Fryauff DJ, McElroy PD, Leksana B, Richie T, Lm Masbar S, Wignall FS, Hoffman SL, 1995. Treatment of chloroquine-resistant Plasmodium vivax with chloroquine and primaquine or halofantrine. J Infect Dis 171 : 1678–1682.
  31. Gogtay NJ, Kshirsagar NA, Vaidya AB, 2006. Current challenges in drug-resistant malaria. J Postgrad Med 52 : 241–242.
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2008.78.736
Loading
/content/journals/10.4269/ajtmh.2008.78.736
Loading

Data & Media loading...

  • Received : 06 Jul 2007
  • Accepted : 26 Jan 2008

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error